OncoMatch/Clinical Trials/NCT06800313
Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Is NCT06800313 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including HLD-0915 Hard Capsule and HLD-0915 Tablet for metastatic prostate cancer.
Treatment: HLD-0915 Hard Capsule · HLD-0915 Tablet · HLD-0915 Soft Capsule — Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV
Metastatic disease required
metastatic prostate cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen-deprivation therapy — mCRPC
Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone
Must have received: androgen receptor pathway inhibitor — mHSPC
treatment with next generation ARPI for at least 180 days and up to 365 days
Cannot have received: cytotoxic chemotherapy for prostate cancer
Has received any prior cytotoxic chemotherapy for prostate cancer
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Yale - New Haven Hospital - Yale Cancer Center · New Haven, Connecticut
- Florida Cancer Specialists · Sarasota, Florida
- Massachusetts General Hospital · Boston, Massachusetts
- START Midwest, LLC · Grand Rapids, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06800313 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy for prostate cancer disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages